<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>9972605</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Alvaro, D</dc:author>
<dc:author>Alvarez-Sala, R</dc:author>
<dc:author>Pino, J M</dc:author>
<dc:author>Fernández, M A</dc:author>
<dc:author>Villamor, J</dc:author>
<dc:author>Prados, C</dc:author>
<dc:author>Gómez de Terreros Caro, J</dc:author>
<dc:description xml:lang="en">Tuberculosis is an infectious disease produced by Mycobacterium tuberculosis in a 98-99% of the cases and by Mycobacterium bovis in a 1-2%. Its early diagnosis is of a great importance because permits to reduce the transmission of the infection. Until now, the diagnostic techniques used to discover the dissemination of the disease are indirect. We have the PPD skin test and, among them, Mantoux is the most common. Correctly used it has a great diagnostic and epidemiological value, because it permits to evaluate those patients who can obtain a benefit with the chemoprophylaxis when the skin test is positive. We analyse the actual via of chemoprophylaxis, when and how it must be used. We study not only the drugs for the prophylaxis, but also the good and bad utilisation of the BCG vaccine, that it starts to have its indications in other countries.</dc:description>
<dc:type>Comparative Study</dc:type>
<dc:language>es</dc:language>
<dc:date>1998 Dec </dc:date>
<dc:title xml:lang="es">Evaluación de los nuevos programas de prevención de la infección tuberculosa. I: quimioprofilaxis.</dc:title>
<dc:title xml:lang="en">[Evaluation of new programs to prevent tuberculosis infection. I. Chemoprophylaxis].</dc:title>
<dc:publisher>Anales de medicina interna (Madrid, Spain : 1984)</dc:publisher>
</metadata>
</record>
</pubmed-document>
